Produktname:3-Methyl-5,6,7,8-tetrahydro-thiazolo[3,2-a][1,3]-diazepine-2-carboxylic acid
IUPAC Name:3-methyl-5H,6H,7H,8H-[1,3]thiazolo[3,2-a][1,3]diazepine-2-carboxylic acid
| Packungseinheit | Verfügbarer Vorrat | Preis($) | Menge |
|---|---|---|---|
| CM527116-1g | in stock | IJǤƿ |
|
|
|||
| Product Overview |
3-Methyl-5,6,7,8-tetrahydro-thiazolo[3,2-a][1,3]-diazepine-2-carboxylic acid, also known as 3MTD, is an organic compound with a molecular formula of C9H10N2O2S. It is a member of the thiazolodiazepine family, which is a class of compounds characterized by a thiazole ring fused to a diazepine ring. 3MTD has a wide range of biological activities, including anticonvulsant, anti-inflammatory, and anti-epileptic effects. It has been studied for its potential therapeutic applications in the treatment of epilepsy, depression, anxiety, and other neurological disorders. |
| Synthesis and Application |
3-Methyl-5,6,7,8-tetrahydro-thiazolo[3,2-a][1,3]-diazepine-2-carboxylic acid can be synthesized through a multi-step process involving the reaction of 2-amino-3,3-dimethylbutan-1-ol with ethyl chloroformate, followed by reaction with thiourea and subsequent hydrolysis. The reaction is carried out in a solvent such as ethanol or dimethylformamide. The yield of the reaction is typically around 70%. 3-Methyl-5,6,7,8-tetrahydro-thiazolo[3,2-a][1,3]-diazepine-2-carboxylic acid has been studied for its potential therapeutic applications in the treatment of epilepsy, depression, anxiety, and other neurological disorders. In animal studies, 3-Methyl-5,6,7,8-tetrahydro-thiazolo[3,2-a][1,3]-diazepine-2-carboxylic acid has been found to possess anticonvulsant and anti-epileptic effects, as well as anti-inflammatory and neuroprotective effects. It has also been shown to reduce the severity of seizures in mice and rats. |
| Future Directions |
The potential therapeutic applications of 3-Methyl-5,6,7,8-tetrahydro-thiazolo[3,2-a][1,3]-diazepine-2-carboxylic acid are still being explored. Future research could focus on the development of new formulations of 3-Methyl-5,6,7,8-tetrahydro-thiazolo[3,2-a][1,3]-diazepine-2-carboxylic acid that have improved pharmacokinetic and pharmacodynamic profiles. Additionally, further studies could be conducted to evaluate the efficacy and safety of 3-Methyl-5,6,7,8-tetrahydro-thiazolo[3,2-a][1,3]-diazepine-2-carboxylic acid in clinical trials. Other potential areas of research include the development of new methods for synthesizing 3-Methyl-5,6,7,8-tetrahydro-thiazolo[3,2-a][1,3]-diazepine-2-carboxylic acid, as well as the exploration of its potential uses in the treatment of other neurological disorders. |
Suche 
+86 21 5895 0110 
